High Yield Adjuvant for Monoclonal Antibody Production
The GERBU Adjuvant MTM is developed specifically for monoclonal antibody production and offers a high yield of IgG and fused
Read more
monoclonal antibodies
FDA Grants EUA for InflaRx’s Gohibic (vilobelimab) to Treat Critically Ill COVID-19 Patients
InflaRx N.V., a biopharmaceutical company in the clinical stage of developing anti-inflammatory therapeutics that target the complement system, has announced
Read more
GERBU Adjuvants – Ready to Use Immunoadjuvants for Better Results
GERBU’s Ready-to-use Immunoadjuvants are Economical and Animal Friendly A GERBU Biotechnik .pdf Brochure The unique GERBU Adjuvant PluS, Adjuvant S,
Read more
EC Approves Sanofi and Regeneron’s Dupixent® for Eosinophilic Esophagitis
The European Commission has authorised Sanofi and Regeneron’s Dupixent® (dupilumab) as the first and only therapeutic therapy for eosinophilic esophagitis.
Read more
AstraZeneca’s Evusheld Becomes First FDA Authorised Antibody Therapy to Prevent COVID-19
Evusheld, a long-acting antibody (LAAB) combination from AstraZeneca, has received emergency use authorisation (EUA) by the FDA in the United
Read more
Phase 3 Data Support ADUHELM™ Ability to Reduce Alzheimer’s Disease Clinical Decline
New Phase 3 Data has shown a positive correlation between the human monoclonal antibody ADUHELM™ treatment effect on biomarkers and
Read more
Genentech’s Investigational Antibody Wins BTD for Alzheimer’s Treatment
Genentech’s investigational antibody for the treatment of early-stage Alzheimer’s disease, Gantenerumab, has been granted Breakthrough Therapy Designation by the U.S.
Read more
Tezepelumab gets ODD in the US for Eosinophilic Esophagitis
Tezepelumab, developed by AstraZeneca in collaboration with Amgen, has been granted Orphan Drug Designation (ODD) in the US FDA for
Read more
Phase 3 Results for Adjuvant Treatment with Merck’s KEYTRUDA® Show Superior RFS in Patients With Resected High-Risk Stage II Melanoma
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced on Saturday the first results from the
Read more
First Celiac Disease Patient Dosed in Calypso IL-15 Monoclonal Antibody Trial
Calypso Biotech, a leading biotechnology company in the development of Interleukin-15 (IL-15) targeted therapies, announces today completion of the dosing
Read more